Dr. Thomas D. Coates, MD
Pediatric Hematology & Oncology (Pediatric Hematology & Oncology Physician)
4650 W Sunset Blvd
Los Angeles, CA 90027
Who else practices at this address →
Los Angeles County includes primary care (7% of residents) and mental health (13% of residents) shortage areas. About shortage areas
- Medicare participating
At a glance
- Medical school
- University of Michigan Medical School (1975)
- Years since graduation
- 51
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 13
Licensed in California since 1985, according to the Medical Board of California. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1975Medical school: University of Michigan Medical School
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Pediatric Hematology & Oncology Physician primary
CA license G56123 (first issued 1985; current)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Children's Hosp of Los Angeles Los Angeles, CA
Medical groups
- Childrens Hospital Los Angeles Medical Group Inc (295 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 13
- Services billed
- 29
- Patients’ average age
- 35
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Payments from drug and device companies
In 2025, 3 companies reported 9 payments worth $5,864 in total to this clinician.
| Agios Pharmaceuticals, Inc. | $5,187 |
|---|---|
| Chiesi USA, Inc. | $648 |
| Novo Nordisk Inc | $29.39 |
| Consulting Fee | $4,827 |
|---|---|
| Travel and Lodging | $648 |
| Food and Beverage | $389 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Agios Pharmaceuticals, Inc. May 30, 2025 | Consulting Fee PYRUKYND · Genetically Defined Disease | $1,750 |
| Agios Pharmaceuticals, Inc. Jun 20, 2025 | Consulting Fee PYRUKYND · Genetically Defined Disease | $1,500 |
| Agios Pharmaceuticals, Inc. Jul 2, 2025 | Consulting Fee PYRUKYND · Genetically Defined Disease | $1,500 |
| Chiesi USA, Inc. Nov 13, 2025 | Travel and Lodging FERRIPROX · TREAT IRON OVERLOAD FROM THALASSEMIA, SICKLE CELL OR ANOTHER ANEMIA · travel to WASHINGTON, DC | $648 |
| Agios Pharmaceuticals, Inc. Dec 8, 2025 | Consulting Fee PYRUKYND · Genetically Defined Disease | $76.92 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 2 industry-funded studies in 2025, from 2 companies. The companies reported $29,878 in research payments for these studies, mostly to the institutions running them.
- A Phase 3b, open label, single-arm rollover study to evaluate long term safety in subjects who have participated in other Luspatercept (Ace-536) clinical trials.
Celgene Corporation - Study of Safety & PK of Luspatercept (ACE-536) in Pediatric Participants With Beta (β)-Thalassemia
E.r. Squibb & Sons, L.l.c. · Recruiting · NCT04143724
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.